BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange.


We unite AI with cutting-edge science to discover life-changing medicines.

Through the combined capabilities of its AI platform, its scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods.

The Benevolent Platform™ powers BenevolentAI’s in-house drug pipeline and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Our pipeline

Reports and presentations

Date and title 16 Mar 2023
Preliminary results for year ended 31 December 2022
Document View
Presentation View
Webcast Watch

All reports and presentations


All announcements

Financial calendar

Date to be announced
2023 AGM
Date to be announced
Interim results for the six months ended 30 June 2023

Full calendar

Investors - Email Alerts.jpg


Get alerts for our announcements

Investor events, conference attendance and annual reporting.

Sign up